IMR Press / FBL / Volume 14 / Issue 7 / DOI: 10.2741/3396

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Murine atherosclerotic plaque imaging with the USPIO Ferumoxtran-10
Show Less
1 Medizinische Klinik und Poliklinik I, Universitaetsklinik Wuerzburg, Germany
2 Experimentelle Physik 5, Universitaet Wuerzburg, Germany
Academic Editor:Fabian Kiessling
Front. Biosci. (Landmark Ed) 2009, 14(7), 2546–2552;
Published: 1 January 2009
(This article belongs to the Special Issue Molecular imaging in cancer)

In this study we intended to image plaque inflammation in a murine model of atherosclerosis with MRI and Ferumoxtran-10 (Sinerem®, Guerbet, France). 8 apoE-/- mice were injected 500µmol Fe/kg or 1000µmol Fe/kg Ferumoxtran-10. 2 apoE-/- mice were injected NaCl. After a post-contrast time of 24 to 336 hours the mice were scarificed and the aortas were imaged ex vivo. All measurements were performed on a 17.6 Tesla Bruker AVANCE 750WB MR scanner (Bruker, Germany). Spin-echo sequences and gradient-echo sequences with variable TE were performed and T2* maps were generated. Prussian-blue and hematoxilin-eosin histology were obtained afterwards and iron-uptake was quantified by counting iron positive areas. 2 apoE-/- mice were imaged in vivo before and 48 hours after 1000µmol Fe/kg. Atheroma iron uptake was not elevated after 24 hours compared to controls. 48 hours after 1000µmol Fe/kg but not 500µmol Fe/kg histology revealed a 1.3- fold increase in plaque iron content compared to NaCl injected mice. Normalized T2*-times decreased from 0.86±0.02 in controls to 0.66±0.15 after a dose of 500µmollFe/ml and 0.59±0.14 in mice injected with 1000µmol Fe/Kg (p=0.038). These results translated into a mean of 122% increase in CNR, as measured by in vivo MRI. We have demonstrated that Ferumoxtran-10 is taken up by atherosclerotic plaques in untreated apoE-/- mice and this alters plaque signal properties.

Back to top